Nidha Iqbal Shapoo

Internist | 🎗️ Oncologist by training | ✍️ Narrative writer | 🎨 Acrylic painter #AIIMSNewDelhi #NYMC

[Nidha Iqbal Shapoo @NidhaShapoo]

@thenasheffect @OUCollegeofMed @GaryRaskob @OU_President @StephensonCC @HMAbushukair @Ayeshaaijaz @minh_phanOK @OncologyScience @neerajaiims Congratulations 🎉

[Nidha Iqbal Shapoo @NidhaShapoo]

Excited to share my new reflection.
What does it mean to care for a patient you may never identify?
“Unknown Chicago” reflects on humanity, dignity, and the silent stories we hold in medicine.
https://t.co/ZoDQAZlyNy
@oncodaily @OncoAlert @PalliativeMed_j @ACEedu @WimedicineOrg @Humanity

[Nidha Iqbal Shapoo @NidhaShapoo]

Pain is not always visible.
And sometimes, it is not believed.

My new reflection, “The Pain We Don’t Trust,” explores the quiet space between patient suffering and medical skepticism.

#NarrativeMedicine #MedTwitter #PatientVoices @oncodaily

https://t.co/BBfHSdLi8j

[Nidha Iqbal Shapoo @NidhaShapoo]

Physicians spend years sitting on one side of the table.
Sometimes life teaches us what it means to be on the other.

My narrative essay “The Other Side of the Table” is now published.

A reflection on vulnerability, empathy, and the humanity that lives between doctor and patient.

PMID: 41817203
DOI: 10.1177/10966218261432014

#NarrativeMedicine #MedTwitter #Oncodaily @oncodaily

[Nidha Iqbal Shapoo @NidhaShapoo]

Solid tumors can drive significant coagulation disorders — from venous & arterial thromboembolism to DIC — worsening outcomes in cancer patients. Better awareness & management strategies needed! @oncodaily @HematologyRepo1

https://t.co/EsJcJWgPdZ

[Nidha Iqbal Shapoo @NidhaShapoo]

AMA poster presentation. Happy to meet a large medical community.
Opioid induced constipation is a crises, sometimes extremely hard to manage leading to complications. Naldemedine can be a life saver. Important topic for all medical specialties.
#MedTwitter #americanmedicalassociation #WashingtonDC #Naldemedine #opioidinducedconstipation @oncodaily @IMG_Oncologists

[International Lung Cancer Summit @LungSummit]

How far have we really come in treating small cell lung cancer?

At ILCS 2025, @RManochakian summarized the entire management of SCLC on a single slide: from surgery and chemoradiation in limited-stage disease to first-line chemo-immunotherapy and second-line tarlatamab or lurbinectedin.
Progress is steady, but the fight continues.

Watch his full talk ⬇️
https://t.co/FgvH9EalYu

[Rami Manochakian MD, FASCO Cancer Education @RManochakian]

🔥🚨#November is 🫁
#LungCancerAwareness Month.

Lung Cancer Awareness #SavesLives.

Together, WITH #Patients, we keep the #Fight against #LungCancer.

We have made a great #Progress but still have a long way to go. #LCAM25

👇🏼Sharing, like every year, my #AWARENESS #Mnemonic

[JAMA Oncology @JAMAOnc]

Glucagon-like peptide-1 receptor agonists (#GLP1s) are associated with a reduced overall #cancer risk in adults with #obesity, lowering the risk for endometrial, ovarian, and meningioma cancers. https://t.co/YnZYJhFJBd

[Nidha Iqbal Shapoo @NidhaShapoo]

Naldemedine: the game changer in refractory opioid-induced constipation.

[Dr Amol Akhade @SuyogCancer]

🚨 ESMO 2025 | LBA15 (AIIMS Delhi)
🧬 Low-dose Pembrolizumab in TNBC
Phase II RCT: Pembrolizumab 50 mg q6wk × 3 + NACT vs NACT alone
👉 pCR 53.8% vs 40.5% (Δ 13.3%, p = 0.047)
➡️ Nearly matches KN-522 results at a fraction of the dose and cost.
💊 Grade ≥ 3 AEs: 50% vs 59.5%
📍Funded by ICMR | Conducted at AIIMS New Delhi
💡 Conclusion: Low-dose pembrolizumab shows comparable efficacy to standard dosing with manageable toxicity.
In LMICs, this could be a viable, affordable immunotherapy pathway.
#ESMO25 @OncoAlert

[Nidha Iqbal Shapoo @NidhaShapoo]

Happy to share my perspective- On Teaching - Journal of Graduate Medical Education @JournalofGME #MedTwitter #Oncology @WomensHealthMag @HemOncWomenDocs @womeninmedchat

Stethoscope and Motherhood https://t.co/8raNnproAp

[Nidha Iqbal Shapoo @NidhaShapoo]

🚨 America’s Oncology Workforce is shrinking — just as cancer cases are rising.
📉 Oncologists per 100,000 people aged 55+ have decreased, while a 56% increase in new cancer cases is projected by 2040.
🌄 Only 7% of oncologists work in non-metro areas.
👩‍⚕️ 25% are nearing retirement.

And yet, hundreds of foreign-trained oncologists face H-1B visa bottlenecks—delays, lotteries, caps—that keep them from serving where they’re needed most.

Cancer doesn’t wait. Visa reform can’t either.
#OncologyWorkforce #H1B #CancerCare #ASCO #VisaCrisis #HealthPolicy #MedTwitter #OncoTwitter

[Nidha Iqbal Shapoo @NidhaShapoo]

Honored to be Sigma Xi full member @MedTwX @oncodaily @OncoAlert

[Nidha Iqbal Shapoo @NidhaShapoo]

🚀 Grateful milestone: my research has now been cited almost 3,000 times.
Honored to see my work contributing to the ever-evolving field of oncology and beyond.
Here’s to continued learning, collaboration, and impact. 🌟📚 #OncoTwitter